Pfizer has been upgraded to a buy rating due to its attractive low valuation, robust free cash flow, and a high dividend yield of 6.2%. The company reported better-than-expected Q2 results and raised its full-year revenue guidance, supported by progress in its drug pipeline. However, guidance for COVID-19 product sales was lowered. Technical indicators show positive momentum, though resistance near $30 remains a challenge. Key risks include uncertainties in the drug pipeline, earnings volatility, litigation, and regulatory challenges, but investors are seen as being rewarded for their patience.
Pfizer shares are trading at USD 27.92 on Pluang, showing a modest gain of 0.65% in the last day. The stock offers a high dividend yield of 6.2%, aligning with the article's focus on its income appeal. As of Sep 23, 2026 08:42 WIB, the market cap stands at $158.11 billion, with a typical hold time of 156 days among investors on Pluang.
Pfizer reported a strong quarterly performance, raising its revenue guidance to $61.5 billion driven by a robust non-COVID product portfolio and recent acquisitions. The company is implementing operational efficiency programs aimed at saving $9.7 bil...
Pfizer has been downgraded from Buy to Hold following a roughly 20% total return since last October. The analyst notes that the stock's valuation, currently around 8.7 times EV/EBITDA, offers less downside protection, and near-term earnings visibilit...
Pfizer remains an attractive income stock, yielding 6.22% and trading at 9.3 times the 2026 expected earnings per share. Its non-COVID business is growing operationally by 5%, supported by a strong pipeline and $1.5 billion ahead of its 2026 business...
Pfizer has paused its annual dividend increase for the first time in over a decade, maintaining a quarterly payout of $0.43 throughout 2026. This pause comes despite a strong 6.2% dividend yield and solid adjusted earnings coverage, reflecting cautio...
